Table of contents

  • Brand Names
  • Drug Combinations
  • Chemistry
  • Pharmacologic Category
  • Mechanism of Action
  • Therapeutic Use
  • Pregnancy and Lactation Implications
  • Contraindications
  • Warnings and Precautions
  • Adverse Reactions
  • Toxicological Effects
  • Genes that may be involved
  • Drug Interactions
  • Nutrition/Nutraceutical Interactions
  • Dosage
  • Pharmacokinetics and Pharmacodynamics
  • Special Considerations

Brand Names


Austria: Biodroxil, Duracef; Belgium: Cefadroxil, Duracef; Bulgaria: Biodroxil, Duracef; Cyprus: Amben, Cefadrox; Czech Republic: Biodroxil, Duracef; Estonia: Duracef; Finland: Cefadroxil, Duracef; France: Cefadroxil, Oracefal; Germany: Cefadroxil, Grüncef; Greece: Moxacef; Hungary: Duracef; Italy: Cefadril, Oradroxil; Latvia: Biodroxil, Duracef; Poland: Biodroxil, Droxef, Duracef, Tadroxil; Portugal: Cefacile, Cefadroxil, Ceforal; Romania: Cefadroxil, Cexil; Slovakia: Cedrox, Duracef; Spain: Cefadroxilo, Duracef; Sweden: Cefadroxil, Cefamox; UK: Baxan, Cefadroxil.

North America

Canada: Cefadroxil; USA: Cefadroxil, Duricef.

Latin America

Argentina: Cefacar, Cefacilina, Cefadrox, Cefamar, Cefatenk, Kandicín, Klondroxil, Versatic; Brazil: Cedroxil, Cefadroxil, Cefadroxila, Cefadroxón-Cefadroxil, Cefamox, Celocortín, Neo Cefadril; Mexico: Cefamox, Cepotec, Duracef, Inedif, Kefloxin, Teroxina.


Japan: Dolucefan, Salislon, Sumacef.

Drug combinations

Cefadroxil and Ambroxol


Cefadroxil: C~16~H~17~N~3~O~5~S H~2~O. Mw: 381.40. (1) 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[[amino(4-hydroxyphenyl)acetyl]amino]-3-methyl-8-oxo-, monohydrate, [6R-[6α,7β(R*)]]-; (2)(6R,7R)-7-[(R)-2-Amino-2-(p-hydroxyphenyl)acetamido]-3-methyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid monohydrate. CAS-66592-87-8; CAS-50370-12-2 (anhydrous); CAS-119922-85-9 (hemihydrate)(1974).

Pharmacologic Category

Antibacterials; First Generation Cephalosporins. (ATC-Code: J01DB05).

Mechanism of action

Inhibits bacterial cell wall synthesis by binding to one or more of the penicillin-binding proteins. Usually bactericidal. Inactive against anaerobic bacteria, fungi, and viruses. Active in vitro and in clinical infections against Gram-positive aerobic bacteria such as staphylococci (including penicillinase-producing strains), Streptococcus pyogenes (group A β-hemolytic streptococci), and S. pneumoniae. Oxacillin-resistant staphylococci (methicillin-resistant staphylococci) and most enterococci are resistant. Active in vitro and in clinical infections against Gram-negative aerobic bacteria such as Moraxella catarrhalis, Escherichia coli, Klebsiella, and Proteus mirabilis. Inactive against Acinetobacter, Enterobacter, Morganella morganii, P. vulgaris, and Pseudomonas.

Therapeutic use

Susceptible bacterial infections including group A β-hemolytic streptococcal pharyngitis or tonsillitis, skin and soft tissue infections caused by streptococci or staphylococci, and urinary tract infections caused by Klebsiella, E. coli, and Proteus mirabilis.

Pregnancy and lactiation implications

Adverse events were not observed in animal reproduction studies. Cefadroxil crosses the placenta. Adequate studies have not been completed in pregnant women. Use with caution.

Unlabeled use


Hypersensitivity to cefadroxil, any component of the formulation, or other cephalosporins.

Warnings and precautions

Use with caution in history of penicillin allergy, especially IgE-mediated reactions (e.g. anaphylaxis, angioedema, urticaria). Prolonged use may result in fungal or bacterial superinfection, including C. difficile-associated diarrhea and pseudomembranous colitis. Use with caution in renal impairment. May cause positive direct Coombs’, false-positive urinary glucose test using cupric sulfate, false-positive serum or urine creatinine with Jaffé reaction. Prolonged use may result in superinfection. In neonates, risk of «gasping syndrome» (potentially fatal) due to consumption of benzoic acid (present in oral suspension).



Legal Notice
Privacy Policy
Cookie Policy


Phone: +34-981-780505
Email: genomicmedicine@wagem.org
Location: Sta Marta de, C. P. Babío, S/N, 15165 Bergondo, A Coruña

Copyright © 2023 WAGEM

Add to cart